Commonwealth Equity Services LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,177 shares of the company’s stock, valued at approximately $250,000.
A number of other large investors have also made changes to their positions in the stock. Gladstone Institutional Advisory LLC acquired a new stake in Medpace during the fourth quarter valued at approximately $302,000. Los Angeles Capital Management LLC grew its holdings in shares of Medpace by 34.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 24,039 shares of the company’s stock worth $5,106,000 after purchasing an additional 6,125 shares during the last quarter. AXA S.A. grew its holdings in shares of Medpace by 27.1% in the 3rd quarter. AXA S.A. now owns 44,600 shares of the company’s stock worth $7,010,000 after purchasing an additional 9,500 shares during the last quarter. Gabelli Funds LLC bought a new stake in shares of Medpace in the 3rd quarter worth about $204,000. Finally, Point72 Hong Kong Ltd grew its holdings in shares of Medpace by 218.4% in the 3rd quarter. Point72 Hong Kong Ltd now owns 898 shares of the company’s stock worth $141,000 after purchasing an additional 616 shares during the last quarter. Institutional investors and hedge funds own 82.49% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the company. Guggenheim raised Medpace from a “neutral” rating to a “buy” rating and set a $252.00 price target for the company in a report on Monday, May 8th. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a report on Friday, May 12th. 22nd Century Group restated an “upgrade” rating on shares of Medpace in a research report on Monday, May 8th. Finally, Robert W. Baird lifted their price target on shares of Medpace from $226.00 to $233.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 15th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.00.
Medpace Stock Performance
NASDAQ:MEDP opened at $206.89 on Friday. The company has a market cap of $6.31 billion, a PE ratio of 26.19 and a beta of 1.42. Medpace Holdings, Inc. has a 52-week low of $130.79 and a 52-week high of $241.48. The stock has a 50-day simple moving average of $198.62 and a 200 day simple moving average of $206.52.
Medpace (NASDAQ:MEDP – Get Rating) last announced its quarterly earnings data on Monday, April 24th. The company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.76 by $0.51. Medpace had a return on equity of 75.20% and a net margin of 16.44%. The company had revenue of $434.07 million for the quarter, compared to analysts’ expectations of $402.83 million. During the same quarter in the prior year, the business posted $1.69 EPS. The business’s revenue was up 31.2% compared to the same quarter last year. On average, research analysts predict that Medpace Holdings, Inc. will post 8.11 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CEO August J. Troendle sold 31,648 shares of the company’s stock in a transaction that occurred on Tuesday, April 25th. The stock was sold at an average price of $221.83, for a total value of $7,020,475.84. Following the transaction, the chief executive officer now owns 6,451,371 shares of the company’s stock, valued at $1,431,107,628.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 25.70% of the company’s stock.
About Medpace
(Get Rating)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Articles
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating).
Receive News & Ratings for Medpace Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medpace and related companies with MarketBeat.com’s FREE daily email newsletter.